Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedUpdated from Revision v3.0.1 to v3.0.2, indicating a new release with potential bug fixes or small feature updates. The removal of 'Back to Top' is a minor UI cleanup and does not alter core content.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%
- Check16 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while key content related to lung cancer and pharmacological details has been removed.SummaryDifference3%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check44 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.